Find out how we can help you develop your work
Opportunities available to you
We offer academic researchers from MRC Units and Institutes and collaborating organisations the opportunity to develop their work.
You could access:
• funding to move your research on to the next stage towards a commercial product if you are an MRC-employed scientist
• our expertise in small molecule drug discovery and therapeutic antibody generation, helping to create the next life-changing therapy
We can also arrange for your research reagents, tools and antibodies to be sold on your behalf, generating additional income for your MRC institution.
For more information
To find out more about how we can help you, please follow the links on the left, or Contact Us.
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.